Altogether, the above results suggest that PFD@Gel treatment can remodel the TPME of ccRCC by reducing ECM deposition and blocking the TGF‐β1 signaling pathway, thus lowering tumor stiffness to increase vascular perfusion and alleviate hypoxia for favorable drug delivery and immune cell infiltration. The gene discussed is TGFB1; the disease is nonpapillary renal cell carcinoma.